Zydus Lifesciences Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹1,13,198 Cr
- Book Value
- ₹269.7
- Stock P/E
- 20.9
- Dividend Yield
- 0.09%
- ROE
- 21.3%
- ROCE
- 21.1%
- PEG Ratio
- 1.11
- EV/EBITDA
- 13.8
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Zydus Lifesciences Ltd closed at ₹1,104.50 on 19 August 2026, down 1.0% on the day, 1.6% below its 50-day average, 8.3% below its 52-week high, with volume at 0.82× its 20-session average.
- RSI 14
- 43.9
- vs 50-day SMA
- -1.6%
- vs 200-day SMA
- +12.6%
- From 52-week high
- -8.3%
- Relative volume
- 0.82×
- 20-day return
- -1.9%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
Zydus Lifesciences share price today
Zydus Lifesciences (NSE: ZYDUSLIFE) combines a 31% operating margin, 21% returns on equity and capital, and an 18.8% five-year profit CAGR — yet trades at 20.9× earnings with a PEG of 1.1, while peers of similar quality trade at 35–40×.
The discount has reasons: heavier US generics exposure and a debt-to-equity ratio of 0.46 that peers do not carry. The question is whether those risks justify a 45% valuation gap.
What the discount overlooks
Zydus is more than a US generics house. The domestic branded business compounds quietly. Vaccines (including India’s first indigenous ZyCoV-D platform know-how) and biologics add depth. A specialty ladder — Saroglitazar in liver disease is the flagship — offers genuine innovation optionality that a 21× multiple pays nothing for. Meanwhile the US business keeps winning limited-competition launches (transplant, oncology niches) that carry generic labels but specialty economics for their exclusivity windows.
What matters next: US price erosion each quarter, FDA outcomes across its plants, the debt trajectory (0.46 D/E is manageable, not pristine), and whether Saroglitazar’s global trials convert optionality into earnings.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹1,13,198 Cr |
| P/E (TTM) | 20.9 |
| EV/EBITDA | 13.8 |
| Operating margin | 31.2% |
| ROE / ROCE | 21.3% / 21.1% |
| Debt to equity | 0.46 |
| Sales CAGR (5y) | 12.5% |
| Profit CAGR (5y) | 18.8% |
| Promoter holding | 75.0% (zero pledged) |
| EPS (TTM) | ₹54.2 |
Zydus Lifesciences share price target 2026 to 2030
EPS base ₹54.2 (TTM). Bear: US price erosion accelerates and a plant hits FDA trouble — 6% growth, multiple stays 17×. Base: 12% growth, modest re-rate to 24× as debt reduces. Bull: specialty (Saroglitazar) lands and the discount closes — 16% growth at 30×.
From ₹1,130, the base case is ≈ +103% over four and a half years — a double from a stock whose multiple starts at 21 rather than 60. The bear case is roughly +9%. The arithmetic does not require heroic assumptions, though the discount can persist if US erosion or debt reduction disappoints.
What supports the case
- The valuation: quality-comparable pharma at 21× when the peer set trades at 35×+ — PEG 1.1.
- 31% operating margin — the P&L already runs at premium-pharma quality.
- Specialty optionality (Saroglitazar, biologics, vaccines) priced at zero.
- Limited-competition US launches keep surprising against the “generics erosion” narrative.
- 75% promoter holding, zero pledge.
The risks: US generic pricing is the permanent headwind, FDA risk applies to every Indian pharma plant, and leverage (0.46 D/E) removes some margin for error that debt-free peers keep.
What to weigh at the current price
The tension is whether domestic brands and specialty assets can close the peer valuation gap before US price erosion, FDA risk or leverage prove the discount justified.
FAQ
What is the Zydus Lifesciences share price target for 2030? The table above sets out bear, base and bull scenarios for each year to 2030. They are valuation sensitivities, not promised prices.
Why is Zydus cheaper than Sun Pharma or Abbott India? Higher US generics mix (price-erosion exposure) and some balance-sheet leverage. The market prices those risks heavily — our view is too heavily, given the margin profile and specialty pipeline.
What is Saroglitazar and why does it matter? A Zydus-discovered drug for fatty-liver disease (MASH) — one of pharma’s largest unmet markets. Global success would re-rate the company from generics maker to innovator; the current price assumes nothing for it.
When are Zydus’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.